Insight Molecular Diagnostics Inc. — Director's Dealing 2019

Sep 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2019-09-17

Reporting Person: Arno Andrew (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-09-17	Common Stock, no par value	P	50000	$2.1626	Acquired	102447	Direct

Footnotes

F1: The price of $2.1626 per share represents a weighted average of prices ranging from $2.11 to $2.21 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.